Search research articles
Contact Us
Filters
Showing results (301-310 of 338) with videos related to
Page
of 34
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
April 5, 2016
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages
Teresa E Peterson, Nathaniel D Kirkpatrick, Yuhui Huang, et al.
Cancer Biomarkers : Section a of Disease Markers
|
September 13, 2024
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab
Yehia I Mohamed, Sunyoung S Lee, Tarik Demir, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2016
PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity
Joao Incio, Josh Tam, Nuh N Rahbari, et al.
Journal for Immunotherapy of Cancer
|
November 25, 2020
Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma
Kohei Shigeta, Aya Matsui, Hiroto Kikuchi, et al.
Cancer Cell
|
January 16, 2007
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T Batchelor, A Gregory Sorensen, Emmanuelle di Tomaso, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 18, 2020
Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists
Alice Y Ho, Jean L Wright, Rachel C Blitzblau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2009
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study
Andrew X Zhu, Dushyant V Sahani, Dan G Duda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 2020
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
Lakshmi Nayak, Annette M Molinaro, Katherine Peters, et al.
Cancer Immunology Research
|
January 23, 2024
Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD-1 Therapy
Jiang Chen, Zohreh Amoozgar, Xin Liu, et al.
Scientific Reports
|
March 10, 2017
Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors
Yunching Chen, Ya-Chi Liu, Yun-Chieh Sung, et al.
Page
of 34
Search research articles
Search
Showing results (301-310 of 338) with videos related to
Sort By:
Page
of 34
Proceedings of the National Academy of Sciences of the United States of America
|
April 5, 2016
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages
Teresa E Peterson, Nathaniel D Kirkpatrick, Yuhui Huang, et al.
Cancer Biomarkers : Section a of Disease Markers
|
September 13, 2024
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab
Yehia I Mohamed, Sunyoung S Lee, Tarik Demir, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2016
PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity
Joao Incio, Josh Tam, Nuh N Rahbari, et al.
Journal for Immunotherapy of Cancer
|
November 25, 2020
Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma
Kohei Shigeta, Aya Matsui, Hiroto Kikuchi, et al.
Cancer Cell
|
January 16, 2007
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T Batchelor, A Gregory Sorensen, Emmanuelle di Tomaso, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 18, 2020
Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists
Alice Y Ho, Jean L Wright, Rachel C Blitzblau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2009
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study
Andrew X Zhu, Dushyant V Sahani, Dan G Duda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 2020
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
Lakshmi Nayak, Annette M Molinaro, Katherine Peters, et al.
Cancer Immunology Research
|
January 23, 2024
Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD-1 Therapy
Jiang Chen, Zohreh Amoozgar, Xin Liu, et al.
Scientific Reports
|
March 10, 2017
Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors
Yunching Chen, Ya-Chi Liu, Yun-Chieh Sung, et al.
Page
of 34